Program Overview

According to published statistics, heart disease and stroke are the leading causes of hospitalization. Further, one third of all men and women in Canada die from cardiovascular disease (CVD). It is therefore one of the most important disease areas and clinical challenges for family physicians to understand and effectively manage.

As a leading medical centre of cardiovascular excellence and part of the University Health Network in Toronto, The Peter Munk Cardiac Centre has dedicated multidisciplinary teams which address the entire spectrum of CVD from innovative cellular research to translation for improved clinical outcomes and collaborations in enhancing patient care with our local community partners. In combination with new and advanced techniques in diagnostic imaging and more effective intervention, these innovations are radically transforming the treatment of cardiovascular disease.

The integrative team philosophy of the Peter Munk Cardiac Centre extends to the critical clinical and communication links with our community partners, especially family physicians, who entrust the Centre with the care of their patients. There is increasing recognition of the need to continue strengthening these links and the continuum of health care provision between our community partners and the Peter Munk Cardiac Centre.

With this goal in mind, we extend this special invitation for you to attend our upcoming 8th Annual Peter Munk Cardiovascular Symposium on January 22nd and 23rd, 2016. Please note that attendance is limited, so we ask that you register as soon as possible while space is still available.

Learning Objectives

The overall aim of this symposium is to highlight optimal assessment and management of patients at risk for the complications of CVD, through discussion of the latest thinking and best practices for office-based patient assessment with emphasis on an integrative patient-focused approach.

After attending this symposium, you will be better able to:

- Discuss the current quality of care for heart failure patients, including the use of advanced therapies and end of life options
- Describe innovations in exercise interventions and new findings in nutrition and heart disease
- Examine the issues and stimulate new ideas around personalized medicine
- Analyze the role of different investigational approaches to treating patients with thoracic aortic aneurysm
- Review appropriate initiation of anticoagulation based on the most recent evidence-based guidelines
- Review indications and future directions of mitral valve imaging and options for replacement
- Evaluate effectiveness and potential limitations of current and emerging pharmacotherapy options for LDL reduction
- Discuss evidence from clinical trials for Type II diabetes patients and relevance to clinical practice

Acknowledgements

Appreciation is expressed to the following for support of this program:

**Patrons:** Bayer, Merck, Novartis, Pfizer-BMS Alliance and Toshiba

**Supporters:** Amgen, Mylan and Sanofi

**Others:** AstraZeneca and Siemens

Registration

This event is sponsored by the Peter Munk Cardiac Centre

As registration is limited, secure your place early at this event.

Register online at:

http://medicaleventsplanning.com/register-pmcs-online/

Target Audience

Family Practitioners, Cardiologists, Radiologists, Internists, Nurses and Allied Health Professionals

(Involved in cardiovascular patient care)

Program Directors

Barry B. Rubin, MD, CM, PhD, FACS, FRSC
Professor of Surgery, University of Toronto
Program Medical Director, Peter Munk Cardiac Centre
Chairman and Chief Executive Officer
MSH UHN Academic Medical Organization

Narinder Paul, MRCP (UK), FRCP, FRCPc
Director, Cardiac Imaging
Toronto General Hospital
Department of Medical Imaging
Associate Professor, University of Toronto

Moderator: Peter J. Lin, MD, CCFP
Director Primary Care Initiatives
Canadian Heart Research Centre
Associate Editor
Elsevier WebPortal - PracticeUpdate Primary Care
Medical Director LinCorp Medical Inc.
“Learning Through Understanding”

Presented by:

Allstream Centre • Exhibition Place
105 Princes’ Boulevard • Toronto • ON • Canada
Program Agenda

FRIDAY, JANUARY 22nd, 2016

12:00 PM Registration and Light Refreshments
12:30 PM Welcome and Introduction
Dr. Barry Adams

Session 1
HEART FAILURE
Chair: Dr. Susanna Mak
12:40 PM Quality Metrics in Heart Failure Care
Dr. Sara Bhuta
1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 2

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 3

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 4

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 5

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 6

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 7

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 8

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

1:00 PM End of Life Care and Palliation in Heart Failure for Specialists and Family Doctors
Dr. Leah Steinberg and Susanna Mak

Innovations
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?

Chair:
CARDIAC REHABILITATION
Session 9

1:45 PM The Role for Ivabradine and Entresto?
1:20 PM New Therapies for Heart Failure: What is the Role for Ivabradine and Entresto?